Business UpdateAug 4, 2026, 07:07 AM
Neuraxis Expands IB-Stim Coverage to Over 500,000 Lives
AI Summary
Neuraxis, Inc. announced additional medical policy coverage for its Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, IB-Stim, expanding access to over 500,000 covered lives in the Mid-Atlantic region. CEO Brian Carrico highlighted the progress with major payers, strengthening the reimbursement network, and building momentum towards comprehensive nationwide coverage. IB-Stim is FDA-cleared for functional abdominal pain associated with irritable bowel syndrome and functional dyspepsia in patients aged 8 and older, addressing a significant unmet medical need.
Key Highlights
- Neuraxis secured additional medical policy coverage for its PENFS technology (IB-Stim).
- The new coverage expands access to over 500,000 additional covered lives.
- This expansion targets beneficiaries in the Mid-Atlantic region.
- CEO Brian Carrico noted progress with payers and strengthening the reimbursement network.
- The company is building momentum towards comprehensive nationwide policy coverage for IB-Stim.
- IB-Stim is FDA-cleared for functional abdominal pain in IBS and Functional Dyspepsia.
- It addresses a significant unmet medical need for pediatric patients with DGBIs.
Price Impact
More from NRXS